NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free DYN Stock Alerts $31.41 0.00 (0.00%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$30.38▼$31.7250-Day Range$23.65▼$35.3852-Week Range$6.40▼$35.98Volume915,257 shsAverage Volume1.65 million shsMarket Capitalization$2.74 billionP/E RatioN/ADividend YieldN/APrice Target$40.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Dyne Therapeutics alerts: Email Address Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside29.8% Upside$40.78 Price TargetShort InterestBearish10.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 6 Articles This WeekInsider TradingSelling Shares$3.50 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.03) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.73 out of 5 starsMedical Sector228th out of 905 stocksPharmaceutical Preparations Industry101st out of 427 stocks 4.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.71% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 2.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 3.3 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Dyne Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,497,318.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.03) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 21.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only AI company to buyIn my new investigation, I detail why this is the single most important factor in the future of AI. I explain what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… You must read this new presentation from Porter Stansberry. About Dyne Therapeutics Stock (NASDAQ:DYN)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesMay 23, 2024 | insidertrades.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 30,426 Shares of StockMay 18, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 2,588 SharesMay 31, 2024 | americanbankingnews.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)May 30, 2024 | globenewswire.comDyne Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesMay 23, 2024 | bizjournals.comThe Petri Dish: Dyne’s public offering, Kronos’ new CFOMay 22, 2024 | forbes.comUp 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?May 22, 2024 | markets.businessinsider.comDyne Therapeutics Prices Public Offering Of 10.50 Mln Shares At $31.00/shrMay 21, 2024 | globenewswire.comDyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockMay 21, 2024 | seekingalpha.comDyne Therapeutics: Progress Undenied In DM1 And DMD TrialsMay 21, 2024 | finance.yahoo.comAnnouncement of The Shaw Laureates 2024May 20, 2024 | msn.comWhy Is Dyne Therapeutics Stock Soaring On Monday?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dyne Therapeutics (DYN)May 20, 2024 | finance.yahoo.comWhy Dyne Therapeutics, With A 166% Run This Year, Just Catapulted AgainMay 20, 2024 | globenewswire.comDyne Therapeutics Announces Proposed Public Offering of Common StockMay 20, 2024 | marketwatch.comDyne Therapeutics Shares Rise 23% on Favorable Drug DataMay 20, 2024 | investors.comWhy Dyne Therapeutics, With A 108% Run This Year, Just Catapulted AgainMay 20, 2024 | msn.comPTC Therapeutics, Oragenics, GT Biopharma among healthcare moversMay 20, 2024 | za.investing.comDyne Therapeutics Inc. stock jumps following trial updatesMay 20, 2024 | msn.comDyne Therapeutics announces data from early stage trials of muscular dystrophy treatmentsMay 20, 2024 | marketwatch.comDyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 TreatmentsMay 20, 2024 | markets.businessinsider.comDyne Therapeutics Reports Positive Data From Phase 1/2 ACHIEVE And Phase 1/2 DELIVER StudiesMay 20, 2024 | globenewswire.comDyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsMay 19, 2024 | globenewswire.comDyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETMay 6, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)See More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/05/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$40.78 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside+29.8%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.92% Return on Assets-90.00% Debt Debt-to-Equity RatioN/A Current Ratio21.83 Quick Ratio21.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book21.08Miscellaneous Outstanding Shares87,380,000Free Float69,234,000Market Cap$2.74 billion OptionableOptionable Beta1.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Susanna Gatti High M.B.A. (Age 56)Chief Operating Officer Comp: $754.1kDr. Jonathan McNeill M.D. (Age 39)Chief Business Officer Comp: $662.34kMr. John G. Cox M.B.A. (Age 61)CEO, President & Director Dr. Romesh Subramanian Ph.D. (Age 59)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 38)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerDr. Oxana Beskrovnaya Ph.D. (Age 63)Chief Scientific Officer Comp: $631.08kMs. Amy Reilly (Age 50)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 52)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsDicerna PharmaceuticalsNASDAQ:DRNAAmphastar PharmaceuticalsNASDAQ:AMPHFive Prime TherapeuticsNASDAQ:FPRXProtagonist TherapeuticsNASDAQ:PTGXCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsDekaBank Deutsche GirozentraleBought 20,000 shares on 6/4/2024Ownership: 0.069%Oxana BeskrovnayaSold 30,426 sharesTotal: $1.00 M ($32.96/share)RA Capital Management L.P.Bought 4,954,779 shares on 5/17/2024Ownership: 5.670%Artal Group S.A.Bought 300,000 shares on 5/17/2024Ownership: 1.737%Ikarian Capital LLCSold 250,000 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price target for 2024? 9 Wall Street analysts have issued 12-month price targets for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's share price to reach $40.78 in the next year. This suggests a possible upside of 29.8% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2024? Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN stock has increased by 136.2% and is now trading at $31.41. View the best growth stocks for 2024 here. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.81) earnings per share for the quarter, meeting the consensus estimate of ($0.81). What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC). When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (9.18%), RA Capital Management L.P. (5.67%), Vanguard Group Inc. (3.94%), Janus Henderson Group PLC (3.06%), Vivo Capital LLC (1.90%) and Artal Group S.A. (1.74%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYN) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company| SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes| SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold| SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.